As EZH2 and H3K27me3 expressions lead to transcriptional repression of tumor suppressor genes, including E-cadherin, and promote tumor progression25,26, it is anticipated that inhibition of EZH2 and H3K27me3 would enhance the sensitivity of tumor cells to cisplatin. The gene discussed is CDH1; the disease is neoplasm.